Greenwich LifeSciences (NASDAQ:GLSI) Coverage Initiated by Analysts at Noble Financial

Key Points

• Noble Financial has initiated coverage of Greenwich LifeSciences (NASDAQ:GLSI), assigning it an "outperform" rating and a price target of $45.00, which suggests a potential upside of 289.61% from its current price.
• The company's shares have recently traded around $11.55, with a 52-week low of $8.06 and a high of $16.50, reflecting significant volatility.
• Greenwich LifeSciences is a clinical-stage biopharmaceutical company focusing on developing immunotherapies for HER2/neu-expressing cancers, with its lead candidate, GP2, currently in Phase III clinical trials.

Noble Financial started coverage on shares of Greenwich LifeSciences (NASDAQ:GLSI - Free Report) in a research report released on Wednesday, Marketbeat.com reports. The firm issued an outperform rating and a $45.00 price objective on the stock. Noble Financial also issued estimates for Greenwich LifeSciences' Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at $3.98 EPS and FY2029 earnings at $9.90 EPS.

Greenwich LifeSciences Stock Down 2.1%

NASDAQ GLSI traded down $0.25 during trading hours on Wednesday, hitting $11.93. The company's stock had a trading volume of 28,639 shares, compared to its average volume of 57,925. The stock has a fifty day moving average of $10.80 and a 200 day moving average of $10.56. Greenwich LifeSciences has a twelve month low of $8.06 and a twelve month high of $16.50. The firm has a market capitalization of $162.61 million, a P/E ratio of -8.77 and a beta of 1.65.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). On average, analysts predict that Greenwich LifeSciences will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Greenwich LifeSciences

Hedge funds have recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey acquired a new stake in Greenwich LifeSciences in the second quarter worth $25,000. Wells Fargo & Company MN grew its position in Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock valued at $32,000 after purchasing an additional 1,008 shares in the last quarter. JPMorgan Chase & Co. grew its position in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock valued at $79,000 after purchasing an additional 4,465 shares in the last quarter. Bank of America Corp DE grew its position in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after acquiring an additional 3,168 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.